## CRL: Charles River Laboratories International, Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.15 indicates fundamental undervaluation. Consistent execution (4/4 quarters beat estimates). Caution: overbought RSI (77).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($204.55)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 8
- **Sentiment:** Bullish (Bullish: 6, Bearish: 1)

**1. Charles River Laboratories stock hits 52-week high at $205.55 By Investing.com**
- Source: Investing.com Australia | 20260105T172457 | Bullish | Relevance: 100%
- Charles River Laboratories International Inc. (CRL) shares reached a 52-week high of $205.55, reflecting strong investor confidence and a 28.83% price return over the last six months, despite the stock's RSI indicating it might be overbought. Analysts anticipate profitability this year with a forecasted EPS of $10.34, and management is actively buying back shares. Recent developments include the conclusion of an SEC investigation without enforcement action and several analyst upgrades, highlighting positive sentiment towards the company.

**2. Charles River Labs downgraded to neutral by UBS**
- Source: MSN | 20260104T190829 | Bearish | Relevance: 100%
- UBS has downgraded Charles River Labs (CRL) to a neutral rating from buy, citing a slowdown in CRL's drug development business. This cautious outlook for 2024 is due to a decline in early-stage discovery services.

**3. Charles River Laboratories International Insiders Placed Bullish Bets Worth US$1.25m**
- Source: Yahoo Finance | 20260106T100805 | Bullish | Relevance: 100%
- Over the past year, insiders at Charles River Laboratories International, Inc. made significant bullish bets, purchasing US$1.3 million worth of shares while selling US$974k. The largest individual purchase was by Chairman James Foster for US$1.0 million, indicating a positive outlook on the company's prospects. Despite no recent insider transactions in the last three months, the overall trend suggests growing insider confidence and alignment with shareholders, who collectively own 1.0% of the company's shares.

**4. Charles River Laboratories stock hits 52-week high at $205.55 By Investing.com**
- Source: Investing.com Canada | 20260105T170815 | Bullish | Relevance: 100%
- Charles River Laboratories International Inc. (CRL) stock reached a 52-week high of $205.55, reflecting strong investor confidence and a 28.83% price return over the last six months. Analysts predict profitability this year with a forecasted EPS of $10.34, and the company has been aggressively buying back shares. Recent developments include the conclusion of an SEC investigation without enforcement action and upgrades from BofA Securities and Baird.

**5. Charles River Laboratories stock hits 52-week high at $205.55 By Investing.com**
- Source: Investing.com South Africa | 20260105T170107 | Bullish | Relevance: 100%
- Charles River Laboratories International Inc. (CRL) stock has reached a new 52-week high of $205.55, reflecting an 8.95% increase over the past year and a 28.83% price return in the last six months. This surge in price, despite the company not being profitable in the last year, is driven by strong investor confidence, aggressive share buybacks, and analyst expectations for profitability this year with a forecasted EPS of $10.34. The company has also recently been cleared of an SEC investigation regarding its sourcing of non-human primates.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 3, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-18 | Mizuho | $200 | $174 | +15% |
| 2025-12-15 | Barclays | $215 | $210 | +2% |
| 2025-12-15 | JP Morgan | $190 | $165 | +15% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-18 | Mizuho | main | Neutral |
| 2025-12-15 | Barclays | main | Overweight |
| 2025-12-15 | JP Morgan | main | Neutral |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 1 ($0.50M) |
| Sells | 0 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 47.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 11.9% (+0.5%)
- Blackrock Inc.: 7.8% (+5.5%)
- Wellington Managemen: 6.5% (-15.3%)
- Allspring Global Inv: 4.4% (-4.9%)
- State Street Corpora: 3.7% (-1.5%)

### Key Risks

1. Market regime shift could impact high-beta names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Analyst target momentum: 3 raises (avg +11%) could attract flows.
- Momentum building: MRS_20 improving +3.8% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 0.15 indicates undervaluation relative to growth. Forward P/E 19.8x stretched relative to 7% growth. Analyst sentiment positive (3 raises, avg +11%). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $10.6B |
| Beta | 1.62 |
| 52W Range | $91.86 - $216.71 |
| Short Interest | 5.6% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.15 |
| Forward P/E | 19.8 |
| Current P/E | 21.1 |
| YoY Growth | 6.8% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from 3.9% to 7.7% (+3.8% in 5 days), confirming momentum buildup. Currently in upper STRENGTH zone (4.0-10.0%), cross-sectional ranking at 90th percentile. MRS_5 at 4.3% confirms short-term momentum alignment. AM_20 at 8.6% shows strong absolute momentum above own 20MA. Outperforming sector by 6.1pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (0.62), confirming momentum. RSI overbought at 77, risk of mean reversion. OFD pattern: +FTN (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 7.73% (CS: 91) | Strong |
| RSI_14 | 76.7 | Overbought |
| MACD Histogram | 0.62 | Bullish |
| vs SMA20 | 1.086x | Above |
| vs SMA50 | 1.169x | Above |
| vs SMA200 | 1.360x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $216.09
- **Stop Loss:** $204.55 (5.3% risk)
- **Target:** $239.17 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 114
- **Position Value:** $24,634.26
- **Portfolio %:** 24.63%
- **Risk Dollars:** $1,320.00
- **Risk Per Trade:** 1.32%
- **Modifiers:** L1 110% | L2 120% | Combined 1.32x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | RISK_ON (MEDIUM) | 1.10x |
| L2 Sector | TREND (Zone A) | 1.20x |

*RISK_ON regime with strong participation and low volatility. VIX at 14.75 (6th percentile) with breadth at 63.5% signals healthy risk appetite. Fed dovish expectations and AI/semiconductor momentum are primary drivers, though elevated put/call ratio suggests smart money hedging. Focus on quality growth with awareness of potential complacency.*

### Earnings

**Next:** 2026-02-18 (Est: $2.34)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.34 | $2.43 | +3.9% |
| 2025Q2 | $2.55 | $3.12 | +22.4% |
| 2025Q1 | $2.07 | $2.34 | +12.8% |
| 2024Q4 | $2.53 | $2.66 | +5.2% |

---
*RULE-based L3 | 2026-01-07 08:25 | MRS_20*